The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.
For good or ill for industry in Europe, it now seems likely that the new Unified Patent Court (UPC) will open for business in the next few years and will start to transform European patent litigation. Indeed, the European Commission is talking up the prospect of it opening in 2014, although most think it will be 2015 at the earliest, given all the preparations that have to be made to establish the new court.
Once it does open, the European Patent Office will also start providing the option for applicants of designating a European patent once granted as having unitary effect (the unitary patent, UP) throughout those countries of the EU which have ratified the UPC agreement (other than Italy, which although having signed the UPC Agreement, has, along with Spain, indicated its intention not to participate in the UP.
This article outlines the likely effect of the UPC on pharmaceutical patent litigation in Europe, and the subsidiary question of what role in this will be played by the central division of the UPC, the London branch of which will have jurisdiction over patents in the areas of chemistry, metallurgy and “human necessities”, thereby giving it jurisdiction over patents in the life sciences sector.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
Unified Patent Court, Europe, pharmaceutical, patent litigation, UPC